Industry Newsbiotechvertex pharmaceuticalsearningsrare diseases
Vertex Reports Fiscal-Year Growth And Price Target Raises
|
6.1
Vertex Pharmaceuticals reported fiscal Q4 and full-year 2025 results on February 12, posting $12.0 billion in full-year revenue, up 9%, and Q4 revenue of $3.19 billion, up 10% year-over-year. Following the results, analysts on February 17 raised price targets — Canaccord to $441, Barclays to $607, H.C. Wainwright to $591 — citing continued commercial strength and pipeline progress.
Scoring Rationale
Official Q4 results and analyst upgrades give practical investor signals, limited by company-specific scope and non-AI relevance.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
